Restrictive cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy

Circulation Research

Volumn 121, Issue 7, 2017, Pages 819-837

  Muchtar, Eli ^a   Blauwet, Lori A ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Amyloidosis; Cardiomyopathies; Diagnosis; Hemochromatosis; Sarcoidosis

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BORTEZOMIB; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; FUROSEMIDE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; TAUROURSODEOXYCHOLIC ACID; TORASEMIDE; GENETIC MARKER;

ARTICLE; CARDIAC HEMOCHROMATOSIS; CARDIAC SARCOIDOSIS; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE MARKER; ECHOCARDIOGRAPHY; GENETICS; HEART AMYLOIDOSIS; HEART FAILURE; HEART TRANSPLANTATION; HEMOCHROMATOSIS; HUMAN; NONHUMAN; PATHOGENESIS; PHLEBOTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RESTRICTIVE CARDIOMYOPATHY; STEM CELL TRANSPLANTATION; SURVIVAL; TACHYCARDIA; THERAPY; ANIMAL; BIOPSY; CARDIAC IMAGING; CARDIAC MUSCLE; CARDIOMYOPATHY, RESTRICTIVE; DNA MUTATIONAL ANALYSIS; GENETIC MARKER; GENETIC PREDISPOSITION; HEART VENTRICLE FUNCTION; MOLECULAR DIAGNOSIS; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTIVE VALUE; RISK FACTOR;

ANIMALS; BIOPSY; CARDIAC IMAGING TECHNIQUES; CARDIOMYOPATHY, RESTRICTIVE; DNA MUTATIONAL ANALYSIS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; MYOCARDIUM; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; VENTRICULAR DYSFUNCTION;

EID: 85030620269     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.310982     Document Type: Article

References (106)

1. Beaton A, Mocumbi AO. Diagnosis and Management of Endomyocardial Fibrosis. Cardiol Clin. 2017;35:87–98. doi: 10.1016/j.ccl.2016.08.005.
2. Towbin JA. Inherited cardiomyopathies. Circ J. 2014;78:2347–2356.
3. Sajgalik P, Grupper A, Edwards BS, Kushwaha SS, Stulak JM, Joyce DL, Joyce LD, Daly RC, Kara T, Schirger JA. Current status of left ventricular assist device therapy. Mayo Clin Proc. 2016;91:927–940. doi: 10.1016/j.mayocp.2016.05.002.
4. Katzmann JA. Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev. 2009;30:105–111.
5. Muchtar E, Dispenzieri A, Kumar SK, et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category [published online ahead of print December 16, 2016]. Leukemia. doi: 10.1038/leu.2016.369. https://www.nature.com/leu/journal/vaop/ncurrent/full/leu2016369a.html.
6. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68:1014–1020. doi: 10.1016/j.jacc.2016.06.033.
7. Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH, Butler KR, Boerwinkle E, Solomon SD. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015;372:21–29. doi: 10.1056/NEJMoa1404852.
8. Crotty TB, Li CY, Edwards WD, Suman VJ. Amyloidosis and endomyocardial biopsy: Correlation of extent and pattern of deposition with amyloid immunophenotype in 100 cases. Cardiovasc Pathol. 1995;4:39–42.
9. Longhi S, Quarta CC, Milandri A, Lorenzini M, Gagliardi C, Manuzzi L, Bacchi-Reggiani ML, Leone O, Ferlini A, Russo A, Gallelli I, Rapezzi C. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid. 2015;22:147–155. doi: 10.3109/13506129.2015.1028616.
10. Lee GY, Kim K, Choi JO, Kim SJ, Kim JS, Choe YH, Grogan MA, Jeon ES. Cardiac amyloidosis without increased left ventricular wall thickness. Mayo Clin Proc. 2014;89:781–789. doi: 10.1016/j.mayocp.2014.01.013.
11. Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, Gagliardi C, Milandri A, Rapezzi C, Falk RH. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129:1840–1849. doi: 10.1161/CIRCULATIONAHA.113.006242.
12. Bellavia D, Pellikka PA, Al-Zahrani GB, Abraham TP, Dispenzieri A, Miyazaki C, Lacy M, Scott CG, Oh JK, Miller FA Jr. Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. J Am Soc Echocardiogr. 2010;23:643–652. doi: 10.1016/j.echo.2010.03.027.
13. Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging. 2010;3:333–342. doi: 10.1016/j.jcmg.2009.11.013.
14. Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132:1570–1579. doi: 10.1161/CIRCULATIONAHA.115.016567.
15. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–2412. doi: 10.1161/CIRCULATIONAHA.116.021612.
16. Muchtar E, Derudas D, Mauermann M, et al. Systemic immunoglobulin light chain amyloidosis-associated myopathy: presentation, diagnostic pitfalls, and outcome. Mayo Clin Proc. 2016;91:1354–1361. doi: 10.1016/j.mayocp.2016.06.027.
17. Perfetto F, Bergesio F, Grifoni E, Fabbri A, Ciuti G, Frusconi S, Angelotti P, Spini V, Cappelli F. Different NT-proBNP circulating levels for different types of cardiac amyloidosis. J Cardiovasc Med (Hagerstown). 2016;17:810–817. doi: 10.2459/JCM.0000000000000349.
18. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751–3757. doi: 10.1200/JCO.2004.03.029.
19. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989–995. doi: 10.1200/JCO.2011.38.5724.
20. Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, Swiecicki PL, Scott CG, Grogan M. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014;113:1723–1727. doi: 10.1016/j.amjcard.2014.02.030.
21. van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006;54:2015–2021. doi: 10.1002/art.21902.
22. Muchtar E, Dispenzieri A, Lacy MQ, et al. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (al): the consequence of failure of early recognition [published online ahead of print March 27, 2017]. Ann Med. doi: 10.1080/07853890.2017. http://www.tandfonline.com/doi/abs/10.1080/07853890.2017.1304649?journalCode=iann20.
23. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114:4957–4959. doi: 10.1182/blood-2009-07-230722.
24. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.
25. Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20:163–178. doi: 10.1007/s10741-014-9462-7.
26. 23a. Muchtar E, Dean DS, Dispenzieri A, et al. Prevalence and predictors of thyroid functional abnormalities in newly diagnosed al amyloidosis. J Intern Med. 2017;281:611–619. doi: 10.1111/joim.12617.
27. Dubrey SW, Bilazarian S, LaValley M, Reisinger J, Skinner M, Falk RH. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am Heart J. 1997;134:994–1001.
28. Lin G, Dispenzieri A, Kyle R, Grogan M, Brady PA. Implantable cardio-verter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol. 2013;24:793–798. doi: 10.1111/jce.12123.
29. Grupper A, Park SJ, Pereira NL, Schettle SD, Gerber Y, Topilsky Y, Edwards BS, Daly RC, Stulak JM, Joyce LD, Kushwaha SS. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease. J Heart Lung Transplant. 2015;34:1042–1049. doi: 10.1016/j.healun.2015.03.012.
30. Dispenzieri A, Buadi F, Kumar SK, et al. Treatment of immunoglobulin light chain amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015;90:1054–1081. doi: 10.1016/j.mayocp.2015.06.009.
31. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G, Rustichelli R, Virga G, Merlini G. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103:2936–2938. doi: 10.1182/blood-2003-08-2788.
32. Kastritis E, Leleu X, Arnulf B, et al. A randomized phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL amyloidosis. Clin Lymphoma Myeloma Leuk. 15:e59–e60.
33. Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase ½ study. Blood. 2011;118:865–873. doi: 10.1182/blood-2011-02-334227.
34. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–4549. doi: 10.1200/JCO.2011.37.7614.
35. Sher T, Fenton B, Akhtar A, Gertz MA. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood. 2016;128:1987–1989. doi: 10.1182/blood-2016-06-722496.
36. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02841033?term=daratumumab+al+amyloidosis&rank=1. Accessed May 8, 2017.
37. Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD, Hawkins PN, Pepys MB. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015;373:1106–1114. doi: 10.1056/NEJMoa1504942.
38. Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol. 2016;34:1097–1103. doi: 10.1200/JCO.2015.63.6530.
39. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02312206?term=vital+neod001&rank=1. Accessed May 8, 2017.
40. Davis MK, Lee PH, Witteles RM. Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant. 2015;34:658–666. doi: 10.1016/j.healun.2014.09.006.
41. Grogan M, Gertz M, McCurdy A, Roeker L, Kyle R, Kushwaha S, Daly R, Dearani J, Rodeheffer R, Frantz R, Lacy M, Hayman S, McGregor C, Edwards B, Dispenzieri A. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. World J Transplant. 2016;6:380–388. doi: 10.5500/wjt.v6.i2.380.
42. Gray Gilstrap L, Niehaus E, Malhotra R, Ton VK, Watts J, Seldin DC, Madsen JC, Semigran MJ. Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. J Heart Lung Transplant. 2014;33:149–156. doi: 10.1016/j.healun.2013.09.004.
43. Berk JL, Suhr OB, Obici L, et al; Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–2667. doi: 10.1001/jama.2013.283815.
44. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785–792. doi: 10.1212/WNL.0b013e3182661eb1.
45. Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015;8:117–127. doi: 10.1007/s12265-015-9613-9.
46. Castaño A, Helmke S, Alvarez J, Delisle S, Maurer MS. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail. 2012;18:315–319. doi: 10.1111/j.1751-7133.2012.00303.x.
47. Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010;8:74. doi: 10.1186/1479-5876-8-74.
48. Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, Perlini S, Saraiva MJ, Merlini G. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012;19(suppl 1):34–36. doi: 10.3109/13506129.2012.678508.
49. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819–829. doi: 10.1056/NEJMoa1208760.
50. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01737398?term=nct01737398&rank=1. Accessed May 8, 2017.
51. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01960348?term=aln-ttr02&rank=3. Accessed May 8, 2017.
52. Ericzon BG, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99:1847–1854. doi: 10.1097/TP.0000000000000574.
53. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361:1111–1118. doi: 10.1016/S0140-6736(03)12888-7.
54. Bresnitz EA, Strom BL. Epidemiology of sarcoidosis. Epidemiol Rev. 1983;5:124–156.
55. Pietinalho A, Hiraga Y, Hosoda Y, Lofroos AB, Yamaguchi M, Selroos O. The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis. 1995;12:61–67.
56. Iwai K, Tachibana T, Takemura T, Matsui Y, Kitaichi M, Kawabata Y. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn. 1993;43:372–376.
57. Mehta D, Mori N, Goldbarg SH, Lubitz S, Wisnivesky JP, Teirstein A. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2011;4:43–48. doi: 10.1161/CIRCEP.110.958322.
58. Dumas O, Abramovitz L, Wiley AS, Cozier YC, Camargo CA Jr. Epidemiology of sarcoidosis in a prospective cohort study of U.S. women. Ann Am Thorac Soc. 2016;13:67–71. doi: 10.1513/AnnalsATS.201508-568BC.
59. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234–241.
60. Newman LS, Rose CS, Bresnitz EA, et al; ACCESS Research Group. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170:1324–1330. doi: 10.1164/rccm.200402-249OC.
61. Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore). 1999;78:65–111.
62. Martusewicz-Boros MM, Boros PW, Wiatr E, Kempisty A, Piotrowska-Kownacka D, Roszkowski-Śliż K. Cardiac sarcoidosis: is it more common in men? Lung. 2016;194:61–66. doi: 10.1007/s00408-015-9805-8.
63. Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, Kaikkonen K, Tuohinen S, Haataja P, Kerola T, Kokkonen J, Pelkonen M, Pietila-Effati P, Utrianen S, Kupari M. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131:624–632.
64. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977;63:86–108.
65. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204–1211.
66. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord. 2007;27:89–102.
67. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, Judson MA, Kron J, Mehta D, Cosedis Nielsen J, Patel AR, Ohe T, Raatikainen P, Soejima K. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305–1323. doi: 10.1016/j.hrthm.2014.03.043.
68. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–755.
69. Trachtenberg BH, Hare JM. Inflammatory cardiomyopathic syndromes. Circ Res. 2017;121:803–818. doi: 10.1161/CIRCRESAHA.117.310221.
70. Iannuzzi MC, Iyengar SK, Gray-McGuire C, et al. Genome-wide search for sarcoidosis susceptibility genes in African Americans. Genes Immun. 2005;6:509–518. doi: 10.1038/sj.gene.6364235.
71. Schürmann M, Reichel P, Müller-Myhsok B, Schlaak M, Müller-Quernheim J, Schwinger E. Results from a genome-wide search for predisposing genes in sarcoidosis. Am J Respir Crit Care Med. 2001;164:840–846. doi: 10.1164/ajrccm.164.5.2007056.
72. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol. 2011;4:303–309. doi: 10.1161/CIRCEP.110.959254.
73. Suzuki T, Kanda T, Kubota S, Imai S, Murata K. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest. 1994;106:1021–1024.
74. Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, Machac J, Teirstein A. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133:1426–1435. doi: 10.1378/chest.07-2784.
75. Schouver ED, Moceri P, Doyen D, Tieulie N, Queyrel V, Baudouy D, Cerboni P, Gibelin P, Leroy S, Fuzibet JG, Ferrari E. Early detection of cardiac involvement in sarcoidosis with 2-dimensional speckle-tracking echocardiography. Int J Cardiol. 2017;227:711–716
76. Murtagh G, Laffin LJ, Patel KV, Patel AV, Bonham CA, Yu Z, Addetia K, El-Hangouche N, Maffesanti F, Mor-Avi V, Hogarth DK, Sweiss NJ, Beshai JF, Lang RM, Patel AR. Improved detection of myocardial damage in sarcoidosis using longitudinal strain in patients with preserved left ventricular ejection fraction. Echocardiography. 2016;33:1344–1352. doi: 10.1111/echo.13281.
77. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, Gulenchyn KY, Dekemp RA, Dasilva J, Birnie D, Wells GA, Beanlands RS. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241–248. doi: 10.2967/jnumed.111.090662.
78. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, Kazemian P, Kwong RY, Tokuda M, Skali H, Padera R, Hainer J, Stevenson WG, Dorbala S, Di Carli MF. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329–336. doi: 10.1016/j.jacc.2013.09.022.
79. Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, Crijns HJ. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683–1690. doi: 10.1016/j.jacc.2005.01.047.
80. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969–1977. doi: 10.1161/CIRCULATIONAHA.109.851352.
81. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501–511. doi: 10.1016/j.jcmg.2012.10.021.
82. Aizer A, Stern EH, Gomes JA, Teirstein AS, Eckart RE, Mehta D. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol. 2005;96:276–282. doi: 10.1016/j.amjcard.2005.03.059.
83. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999;138:299–302.
84. Liang JJ, Hebl VB, DeSimone CV, Madhavan M, Nanda S, Kapa S, Maleszewski JJ, Edwards WD, Reeder G, Cooper LT, Asirvatham SJ. Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. JACC Heart Fail. 2014;2:466–473. doi: 10.1016/j.jchf.2014.03.015.
85. Tavora F, Cresswell N, Li L, Ripple M, Solomon C, Burke A. Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes. Am J Cardiol. 2009;104:571–577. doi: 10.1016/j.amjcard.2009.03.068.
86. Kandolin R, Lehtonen J, Graner M, Schildt J, Salmenkivi K, Kivistö SM, Kupari M. Diagnosing isolated cardiac sarcoidosis. J Intern Med. 2011;270:461–468. doi: 10.1111/j.1365-2796.2011.02396.x.
87. Tezuka D, Terashima M, Kato Y, Toriihara A, Hirasawa K, Sasaoka T, Yoshikawa S, Maejima Y, Ashikaga T, Suzuki J, Hirao K, Isobe M. Clinical characteristics of definite or suspected isolated cardiac sarcoidosis: application of cardiac magnetic resonance imaging and 18F-Fluoro-2-deoxyglucose positron-emission tomography/computerized tomography. J Card Fail. 2015;21:313–322. doi: 10.1016/j.cardfail.2014.12.004.
88. Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, Kaikkonen K, Tuohinen S, Haataja P, Kerola T, Kokkonen J, Pelkonen M, Pietilä-Effati P, Utrianen S, Kupari M. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131:624–632. doi: 10.1161/CIRCULATIONAHA.114.011522.
89. Sperry BW, Oldan J, Hachamovitch R, Tamarappoo BK. Insights into biopsy-proven cardiac sarcoidosis in patients with heart failure. J Heart Lung Transplant. 2016;35:392–393. doi: 10.1016/j.healun.2015.12.005.
90. Okada DR, Bravo PE, Vita T, Agarwal V, Osborne MT, Taqueti VR, Skali H, Chareonthaitawee P, Dorbala S, Stewart G, Di Carli M, Blankstein R. Isolated cardiac sarcoidosis: A focused review of an under-recognized entity. J Nucl Cardiol. 2016
91. Kumar S, Barbhaiya C, Nagashima K, Choi EK, Epstein LM, John RM, Maytin M, Albert CM, Miller AL, Koplan BA, Michaud GF, Tedrow UB, Stevenson WG. Ventricular tachycardia in cardiac sarcoidosis: characterization of ventricular substrate and outcomes of catheter ablation. CircArrhythm Electrophysiol. 2015;8:87–93. doi: 10.1161/CIRCEP.114.002145.
92. Muser D, Santangeli P, Pathak RK, Castro SA, Liang JJ, Magnani S, Hayashi T, Garcia FC, Hutchinson MD, Supple GE, Frankel DS, Riley MP, Lin D, Schaller RD, Desjardins B, Dixit S, Callans DJ, Zado ES, Marchlinski FE. Long-term outcomes of catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2016;9.
93. Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol. 2013;29:1034–1041. doi: 10.1016/j.cjca.2013.02.004.
94. Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, Izumi T, Sekiguchi M; Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006–1010.
95. Krause ML, Cooper LT, Chareonthaitawee P, Amin S. Successful use of rituximab in refractory cardiac sarcoidosis. Rheumatology (Oxford). 2016;55:189–191. doi: 10.1093/rheumatology/kev309.
96. Drake WP, Oswald-Richter K, Richmond BW, Isom J, Burke VE, Algood H, Braun N, Taylor T, Pandit KV, Aboud C, Yu C, Kaminski N, Boyd AS, King LE. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol. 2013;149:1040–1049. doi: 10.1001/jamadermatol.2013.4646.
97. Drake WP, Richmond BW, Oswald-Richter K, Yu C, Isom JM, Worrell JA, Shipley GR. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30:201–211.
98. Segura AM, Radovancevic R, Demirozu ZT, Frazier OH, Buja LM. Granulomatous myocarditis in severe heart failure patients undergoing implantation of a left ventricular assist device. Cardiovasc Pathol. 2014;23:17–20. doi: 10.1016/j.carpath.2013.06.005.
99. Zaidi AR, Zaidi A, Vaitkus PT. Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transplant. 2007;26:714–717. doi: 10.1016/j.healun.2007.05.006.
100. Chiu CZ, Nakatani S, Zhang G, Tachibana T, Ohmori F, Yamagishi M, Kitakaze M, Tomoike H, Miyatake K. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005;95:143–146. doi: 10.1016/j.amjcard.2004.08.083.
101. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med. 1988;318:1355–1362. doi: 10.1056/NEJM198805263182103.
102. Gulati V, Harikrishnan P, Palaniswamy C, Aronow WS, Jain D, Frishman WH. Cardiac involvement in hemochromatosis. Cardiol Rev. 2014;22:56–68. doi: 10.1097/CRD.0b013e3182a67805.
103. Kondur AK, Li T, Vaitkevicius P, Afonso L. Quantification of myocardial iron overload by cardiovascular magnetic resonance imaging T2* and review of the literature. Clin Cardiol. 2009;32:E55–E59. doi: 10.1002/clc.20310.
104. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS; American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:328–343. doi: 10.1002/hep.24330.
105. Adams PC, Barton JC. How I treat hemochromatosis. Blood. 2010;116:317–325. doi: 10.1182/blood-2010-01-261875.
106. Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110:1107–1119.